Raedler, L. (2015). Velcade (Bortezomib) Receives 2 New FDA Indications: For Retreatment of Patients with Multiple Myeloma and for First-Line Treatment of Patients with Mantle-Cell Lymphoma. Am Health Drug Benefits.
استشهاد بنمط شيكاغوRaedler, Lisa. "Velcade (Bortezomib) Receives 2 New FDA Indications: For Retreatment of Patients With Multiple Myeloma and for First-Line Treatment of Patients With Mantle-Cell Lymphoma." Am Health Drug Benefits 2015.
MLA استشهادRaedler, Lisa. "Velcade (Bortezomib) Receives 2 New FDA Indications: For Retreatment of Patients With Multiple Myeloma and for First-Line Treatment of Patients With Mantle-Cell Lymphoma." Am Health Drug Benefits 2015.
تحذير: قد لا تكون هذه الاستشهادات دائما دقيقة بنسبة 100%.